Frankfurt
09.04.26 | 15:25
3,385 Euro
-5,05 % -0,180
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | EQS-News: PolyPid vor dem Durchbruch? Warum dieses Biotech-Unternehmen plötzlich in den Fokus rückt (FSE: 2PV) | 326 | EQS Group (DE) | EQS-News: PolyPid
/ Schlagwort(e): Sonstiges
PolyPid vor dem Durchbruch? Warum dieses Biotech-Unternehmen plötzlich in den Fokus rückt (FSE: 2PV)
08.04.2026 / 17:45 CET/CEST
Für... ► Artikel lesen | |
| 01.04. | XFRA NEW INSTRUMENTS AVAILABLE ON 01.04.2026 | 181 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.04.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.04.2026
Aktien
1 SE0010600106 Infrea AB
2 SE0010441139... ► Artikel lesen | |
| 31.03. | PolyPid Ltd.: PolyPid Initiates D-PLEX100 NDA Submission to the FDA | 183 | GlobeNewswire (Europe) | PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31... ► Artikel lesen | |
| 31.03. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.03. | PolyPid receives $4.3M FDA fee waiver for D-PLEX100 application | 1 | Investing.com | ||
| 17.03. | PolyPid Ltd.: PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX100's New Drug Application | 257 | GlobeNewswire (Europe) | FDA Grants $4.3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of this Month PETACH TIKVA, Israel, March 17... ► Artikel lesen | |
| POLYPID Aktie jetzt für 0€ handeln | |||||
| 25.02. | PolyPid Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 11.02. | PolyPid Ltd. Bottom Line Falls In Q4 | 1 | RTTNews | ||
| 11.02. | PolyPid GAAP EPS of -$0.41 misses by $0.08 | 2 | Seeking Alpha | ||
| 11.02. | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | 269 | GlobeNewswire (Europe) | The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX100 Positive FDA Pre-NDA Feedback Supports Rolling NDA Review- Submission Expected to Begin by the End of the... ► Artikel lesen | |
| 10.02. | Preview: PolyPid's Earnings | 1 | Benzinga.com | ||
| 04.02. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.01. | PolyPid Ltd.: PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 | 2 | GlobeNewswire (USA) | ||
| 31.12.25 | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.12.25 | PolyPid Appoints Brooke Story As Chairman Of Board | 4 | RTTNews | ||
| 16.12.25 | PolyPid Ltd.: PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.12.25 | PolyPid: Interview With Chief Operating Officer - U.S. Operations Ori Warshavsky About Preventing Surgical Site Infections | 1 | pulse2.com | ||
| 03.12.25 | FDA unterstützt Zulassungsantrag für D-PLEX100: PolyPid-Aktie legt zu | 3 | Investing.com Deutsch | ||
| 03.12.25 | PolyPid Ltd.: PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX100 Supporting NDA Submission | 156 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,45 | -0,63 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| EVOTEC | 4,526 | -3,21 % | Evotec Aktie: 2 Euro oder 6 Euro - wohin geht es für die Biotech-Aktie? | Nach dem Absturz der Evotec Aktie an die 4-Euro-Marke läuft bei dem Biotech-Titel ein erneuter Versuch einer Bodenbildung. Die zentrale charttechnische Unterstützung hat sich diesmal im Kern bei 3,995/4... ► Artikel lesen | |
| AMGEN | 303,85 | +1,35 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,700 | +2,95 % | Where Will Viking Therapeutics Stock Be in 10 Years? | ||
| DEFENCE THERAPEUTICS | 0,333 | 0,00 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Warrant Terms Amendment | Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,399 | -2,21 % | NurExone Biologic: Erster Platz bei den BOLD Awards! | ||
| ABIVAX | 105,40 | +3,23 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| IBIO | 1,829 | -4,54 % | iBio, Inc.: iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia | IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 55,84 | +1,20 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,372 | +0,84 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| CYBIN | 4,435 | -1,33 % | Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer | Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company... ► Artikel lesen | |
| CAPRICOR | 27,530 | +1,66 % | Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary... ► Artikel lesen | |
| OPGEN | 1,568 | 0,00 % | OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc. | CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC: OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 34,790 | -0,23 % | Weekly Buzz: ARS Pharmaceuticals Gains FDA Nod; Novo Nordisk received FDA approval for Awiqli; EU Expands Kerendia Label; Eli Lilly Acquires Centessa Pharmaceuticals; Biogen Snaps Up Apellis Pharmaceuticals | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,272 | -0,73 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights | Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into... ► Artikel lesen |
POLYPID LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,385 Euro und damit -5,05 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYPID LTD finden Sie auf Wallstreet Online.